Business
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration
About this update from Scynexis, Inc.
[{"type":"image","alt":"Scynexis","displaySize":"","headline":null,"caption":"Scynexis","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":68,"url":"https://media.zenfs.com/en/globenewswire.com/6e640369b5a4d26f13c5b336ff4b47c4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zxf0PtiEj_fhfiPgUpXZlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6e640369b5a4d26f13c5b336ff4b47c4","width":300,"height":68}},"lazy":false},{"type":"text","content":"The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval","length":103,"tagName":"p"},{"type":"text","content":"Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection ","length":123,"tagName":"p"},{"type":"text","content":"JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration (“FDA”) has granted the Company Qualified Infectious Disease Product (QIDP) and Fast Track Designations for its second-generation triterpenoid antifungal therapy, SCY-247.","length":444,"tagName":"p"},{"type":"text","content":"“Receiving FDA’s QIDP and Fast Track designations for SCY-247 reflects the potential of SCY-247 to address the serious unmet need posed by life-threatening resistant fungal infections,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. “Last year we presented results from multiple preclinical efficacy models consistently showing the potent antifungal activity of SCY-247 against a broad array of fungal pathogens, including some of the most difficult to treat such as Candida auris and echinocandin-resistant C. glabrata, as well as data supporting extensive tissue distribution. We also disclosed positive Phase 1 SAD/MAD data that not only demonstrated SCY-247’s promising safety and favorable pharmacokinetic properties, but also showed that the drug could achieve target exposures for invasive fungal disease at doses lower than our first generation fungerp. The data generated to date strongly positions SCY-247 as a unique candidate to address the clear need for novel, safe and potent antif...